ecpm_header_research_1_1.jpg

Publications

Peer-reviewed publications by the European Center of Pharmaceutical Medicine or Institute of Pharmaceutical Medicine Research Team members are referenced below as well as on the personal pages of the team members.

2019

Schneider R, Schur N, Reinau D, Schwenkglenks M, Meier C. Helsana Arzneimittelreport 2019.

Schmucker C, Titscher V, Braun C, Dobrescu A, Klerings I, Nussbaumer-Streit B, Gartlehner G, Meerpohl JJ, Barbier M, Tomonaga Y, Schur N, Menges D, Schwenkglenks M. Comparative effectiveness, safety, and costs of surgical versus non-surgical treatment in patients with full-thickness rotator cuff tears: a systematic review and health economic assessment. Swiss Medical Board, 2019.

Szucs TD, El Saadany T. Learning and Confirming» in Pharmaforschung und -entwicklung. Von Sackgassen und Durchbrüchen. conexus 2019; 2: 63-76. doi: 10.24445/conexus.2019.02.006. https://doi.org/10.24445/conexus.2019.02.006  

Vrinten C, Stoffel S, Dodd RH, Waller J, Lyratzopoulos Y, & von Wagner C (2019). Cancer worry frequency vs. intensity and self-reported colorectal cancer screening uptake: A population-based study. Journal of Medical Screening. December 26, 2019. doi: 10.1177/0969141319842331. https://doi.org/10.1177/0969141319842331  

Witassek F, Springer A, Adam L, Aeschbacher S, Beer JH, Blum S, Bonati LH, Conen D, Kobza R, Kühne M, Moschovitis G, Osswald S, Rodondi N, Sticherling C, Szucs T, Schwenkglenks M. Swiss-AF study investigators. Health-related quality of life in patients with atrial fibrillation: The role of symptoms, comorbidities, and the type of atrial fibrillation. December 23, 2019 PLoS One 2019; 14(12):e0226730. doi: 10.1371/journal.pone.0226730. eCollection 2019. https://doi.org/10.1371/journal.pone.0226730

Bhadhuri A, Insinga R, Guggisberg P, Panje C, Schwenkglenks M. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. Swiss Med Wkly 2019; 149:w20170. December 16, 2019 doi: 10.4414/smw.2019.20170. eCollection. https://doi.org/10.4414/smw.2019.20170

Bhadhuri A, Al-Janabi H, Jowett S, Jolly K. Incorporating Household Spillovers in Cost Utility Analysis: A Case Study Using Behavior Change in COPD. International journal of technology assessment in health care. 2019;35(3):212-20.

Spirk D, Sebastian T, Banyai M, Beer JH, Mazzolai L, Baldi T, Aujesky D, Hayoz D, Engelberger RP, Kaeslin T, Korte W, Escher R, Husmann M, Mollet A,Szucs TD, Kucher N. Venous Thromboembolism and Renal Impairment: Insights from the Swiss Venous Thromboembolism Registry (SWIVTER). Semin Thromb Hemost. 2019 Nov; 45(8):851-858. doi: 10.1055/s-0039-1698770. https://doi.org/10.1055/s-0039-1698770

von Wagner C, Verstraete W, & Stoffel, S (2019). Psychological aspects of cancer screening. In Oxford Research Encyclopedia of Psychology, Oxford University Press. November 2019, doi: 10.1093/acrefore/9780190236557.013.130. https://doi.org/10.1093/acrefore/9780190236557.013.130

Schneider R, Reinau D, Schur N, Blozik E, Früh M, Signorell A, Heininger U, Schwenkglenks M, Meier CR. Coverage rates and timeliness of nationally recommended vaccinations in Swiss preschool children: A descriptive analysis using claims data. Vaccine. 2019; pii: S0264-410X (19)31599-3. doi: 10.1016/j.vaccine.2019.11.057. [Epub ahead of print]. https://doi.org/10.1016/j.vaccine.2019.11.057

Sutherland CS, Ademi Z, Michaud J, Schur N, Lingg M, Bhadhuri A, Pache TD, Bitzer J, Suchon P, Albert V, Hersberger KE, Tanackovic G, Schwenkglenks M. Economic evaluation of a novel genetic screening test for risk of venous thromboembolism compared with standard of care in women considering combined hormonal contraception in Switzerland. BMJ Open 2019; 9(11):e031325. doi: 10.1136/bmjopen-2019-031325. https://doi.org/10.1136/bmjopen-2019-031325

Pillai N, Lupatsch JE, Dusheiko M, Schwenkglenks M, Maillard M, Sutherland CS, Pittet VEH. Swiss IBD Cohort study group. Evaluating the cost-effectiveness of early compared to late or no biologic treatment to manage Crohn's disease using real world data. J Crohns Colitis 2019; pii: jjz169. doi: 10.1093/ecco-jcc/jjz169. [Epub ahead of print]. https://doi.org/10.1093/ecco-jcc/jjz169

Mattli R, Farcher R, Syleouni ME, Wieser S, Probst-Hensch N, Schmidt-Trucksäss A, Schwenkglenks M. Physical Activity Interventions for Primary Prevention in Adults: A Systematic Review of Randomized Controlled Trial-Based Economic Evaluations. Sports Med 2019. doi: 10.1007/s40279-019-01233-3. [Epub ahead of print]. https://doi.org/10.1007/s40279-019-01233-3

Blum S, Aeschbacher S, Meyre P, Zwimpfer L, Reichlin T, Beer JH, Ammann P, Auricchio A, Kobza R, Erne P, Moschovitis G, Di Valentino M, Shah D, Schläpfer J, Henz S, Meyer-Zürn C, Roten L, Schwenkglenks M, Sticherling C, Kühne M, Osswald S, Conen D. Swiss‐AF Investigators. Incidence and Predictors of Atrial Fibrillation Progression. J Am Heart Assoc 2019; 8(20):e012554. doi: 10.1161/JAHA.119.012554. Epub 2019 Oct 8. https://doi.org/10.1161/JAHA.119.012554

Ghanouni A, Waller J, Stoffel ST, Vlaev I, von Wagner C. Acceptability of risk-stratified breast screening: Effect of the order of presenting risk and benefit information. Journal of Medical Screening, October 1, 2019. doi: 10.1177/096914131987766. https://doi.org/10.1177/0969141319877669

von Wagner C, Bonello B, Stoffel ST, Skrobanski H, Kerrison R, McGregor LM, L. Predictors of intention translation in flexible sigmoidoscopy screening for colorectal cancer. Health Psychology. September 26, 2019. doi: 10.1037/hea0000793. doi.org/10.1037/hea0000793 

von Wagner C, Cadar D, Hackett RA, Demakakos P, Beeken RJ, Cooper Bailey S, Wolf M, Steptoe A,  Renzi C, Stoffel ST. Type 2 diabetes and colorectal cancer screening: Findings from the English Longitudinal Study of Ageing. Journal of Medical Screening. September 23, 2019. doi: 10.1177/096914131987483. https://doi.org/10.1177/0969141319874834

Schneider R, Reinau D, Schur N, Blozik E, Früh M, Signorell A, Meier CR, Schwenkglenks M. Drug prescription patterns, polypharmacy and potentially inappropriate medication in Swiss nursing homes: a descriptive analysis based on claims data. Swiss Med Wkly 2019; 149: w20126. doi: 10.4414/smw.2019.20126. eCollection 2019 Sep 23. https://doi.org/10.4414/smw.2019.20126

Speich B, Gloy V, Schur N, Ewald H, Hemkens LG, Schwenkglenks M, Briel M: Making Randomized Trials Affordable (MARTA) Group. A scoping review shows that several nonvalidated budget planning tools for randomized trials are available. J Clin Epidemiol 2020 Jan; 117:9-19. doi: 10.1016/j.jclinepi.2019.09.009. Epub 2019 Sep 15. https://doi.org/10.1016/j.jclinepi.2019.09.009

von Wagner C, Hirst, Y, Waller J, Ghanouni A, McGregor LM, Kerrison RS, Verstraete W, Sieverding M, Stoffel ST (2019). The impact of descriptive norms on motivation to participate in cancer screening – Evidence from online experiments. Patient Education and Counseling. 0738-3991., September 2019. doi: 10.1016/j.pec.2019.04.001. https://doi.org/10.1016/j.pec.2019.04.001  

Jungo KT, Rozsnyai Z, Mantelli S, Floriani C, Löwe AL, Lindemann F, Schwab N, Meier R, Elloumi L, Huibers CJA, Sallevelt BTGM, Meulendijk MC, Reeve E, Feller M, Schneider C, Bhend H, Bürki PM, Trelle S, Spruit M, Schwenkglenks M, Rodondi N, Streit S. 'Optimising PharmacoTherapy In the multimorbid elderly in primary Care' (OPTICA) to improve medication appropriateness: study protocol of a cluster randomised controlled trial. BMJ Open 2019;9(9):e031080. doi: 10.1136/bmjopen-2019-031080. https://doi.org/10.1136/bmjopen-2019-031080

Stoffel ST, Kerrison RS, Vlaev I, von Wagner C. Offering male endoscopists as decoy option to nudge disinclined women to have colorectal cancer screening. Journal of Behavioral Medicine. August 30, 2019. doi: 10.1007/s10865-019-00095-4  https://doi.org/10.1007/s10865-019-00095-4 

Stoffel ST, Yang J, Vlaev I, von Wagner C. Correction: Testing the decoy effect to increase interest in colorectal cancer screening. PloS one, 14(3). July 10, 2019 PLoS One. 2019 Jul 10; 14(7):e0219811. doi: 10.1371/journal.pone.0219811. eCollection 2019. https://doi.org/10.1371/journal.pone.0219811

Glinz D, Gloy VL, Monsch AU, Kressig RW, Patel C, McCord KA, Ademi Z, Tomonaga Y, Schwenkglenks M, Bucher HC, Raatz H. Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis. Swiss Med Wkly 2019; 149: w20093. doi: 10.4414/ smw.2019.20093. eCollection 2019 Jun 17. https://doi.org/10.4414/smw.2019.20093

Adam L, Moutzouri E, Baumgartner C, Loewe AL, Feller M, M'Rabet-Bensalah K, Schwab N, Hossmann S, Schneider C, Jegerlehner S, Floriani C, Limacher A, Jungo KT, Huibers CJA, Streit S, Schwenkglenks M, Spruit M, Van Dorland A, Donzé J, Kearney PM, Jüni P, Aujesky D, Jansen P, Boland B, Dalleur O, Byrne S, Knol W, Spinewine A, O'Mahony D, Trelle S, Rodondi N. Rationale and design of OPtimising thERapy to prevent Avoidable hospital admissions in Multimorbid older people (OPERAM): a cluster randomised controlled trial. June 3, 2019 BMJ Open 2019; 9(6):e026769. doi: 10.1136/bmjopen-2018-026769.

Stoffel ST, Goodwin M, Sieverding M, Vlaev I,von Wagner C. Testing verbal quantifiers for social norms messages: Evidence from an online experiment. BMC public health. May 29, 2019. doi: 10.1186/s12889-019-6997-5 https://doi.org/10.1186/s12889-019-6997-5  

Komann M, Weinmann C, Schwenkglenks M, Meissner W. Non-Pharmacological Methods and Post-Operative Pain Relief: An Observational Study. Anesth Pain Med 2019 Apr 20;9(2):e84674. doi: 10.5812/aapm.84674. eCollection 2019 Apr. https://doi.org/10.5812/aapm.84674

Von Wagner C, Stoffel ST, Freeman M, Laszlo HE, Nicholson B, Sheringham J, Szinay D, Hirst Y. General practitioners' awareness of the recommendations for Faecal Immunochemical Tests (FIT) for suspected lower gastrointestinal cancers: a national survey. BMJ Open. April 11, 2019. 9:e025737. doi: 10.1136/bmjopen-2018-025737. https://doi.org/10.1136/bmjopen-2018-025737

Grossmann R, Schneider MA, Linecker M, Lehn JM, Nicolau C, Traber M, Tay F, Vicente D, Jetter A, Mollet A,Szucs T, Graf R, Clavien PA, Limani P. Interprofessional and interdisciplinary collaboration for early phase oncological clinical trials in academia-Myo-inositoltrispyrophophate as model. Pharmacol Res. 2019 Apr 19:104238. doi: 10.1016/j.phrs.2019.04.022. https://doi.org/10.1016/j.phrs.2019.04.022

Sutherland CS, Tediosi F. Is the elimination of 'sleeping sickness' affordable? Who will pay the price? Assessing the financial burden for the elimination of human African trypanosomiasis Trypanosoma brucei gambiense in sub-Saharan Africa. BMJ Glob Health. 2019 Apr 14;4(2):e001173. doi: 10.1136/bmjgh-2018-001173. eCollection 2019. PMID: 31139437. https://doi.org/10.1136/bmjgh-2018-001173.

Ulyte A, Bähler C, Schwenkglenks M, von Wyl V, Gruebner O, Wei W, Blozik E, Brüngger B, Dressel H. Measuring diabetes guideline adherence with claims data: systematic construction of indicators and related challenges. April 24, 2019 BMJ Open 2019; 9(4):e027138. doi: 10.1136/bmjopen-2018-027138. https://doi.org/10.1136/bmjopen-2018-027138

Conen D, Rodondi N, Müller A, Beer JH, Ammann P, Moschovitis G, Auricchio A, Hayoz D, Kobza R, Shah D, Novak J, Schläpfer J, Di Valentino M, Aeschbacher S, Blum S, Meyre P, Sticherling C, Bonati LH, Ehret G, Moutzouri E, Fischer U, Monsch AU, Stippich C, Wuerfel J, Sinnecker T, Coslovsky M, Schwenkglenks M, Kühne M, Osswald S; Swiss-AF Study Investigators. Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. J Am Coll Cardiol March 12, 2019; 73:989-999. doi: 10.1016/j.jacc.2018.12.039. https://doi.org/10.1016/j.jacc.2018.12.039

Warren E, Morgan K, Toward TJ, Schwenkglenks M, Leadbetter J. Cost Effectiveness of Inhaled Mannitol (Bronchitol®) in Patients with Cystic Fibrosis. Pharmacoeconomics. March 2019; 37:435-46. doi: 10.1007/s40273-019-00767-8. https://doi.org/10.1007/s40273-019-00767-8

Blank PR, Tomonaga Y, Szucs TD, Schwenkglenks M. Economic burden of symptomatic iron deficiency - a survey among Swiss women. BMC Women’s Health. February 26, 2019; 19(1):39. doi: 10.1186/s12905-019-0733-2. https://doi.org/10.1186/s12905-019-0733-2

Stoffel S, Benito L, Milà N, Travier N, Binefa G, Vidal C,Espinosa J, Moreno V, Garcia M Testing behavioural interventions to optimize participation in a population-based colorectal cancer screening program in Catalonia, Spain. Preventive medicine, February 2019; 119, 58-62 https://doi.org/10.1016/j.ypmed.2018.12.013

Mattli R, Wieser S, Probst-Hensch N, Schmidt-Trucksäss A, Schwenkglenks M. Physical inactivity caused economic burden depends on regional cultural differences. Scand J Med Sci Sports. January 29, 2019; 29:95-104. doi: 10.1111/sms.13311. https://doi.org/10.1111/sms.13311

Speich B, Schur N, Gryaznov D, von Niederhäusern B, Hemkens LG, Schandelmaier S, Amstutz A, Kasenda B, Pauli-Magnus C, Ojeda-Ruiz E, Tomonaga Y, McCord K, Nordmann A, von Elm E, Briel M*, Schwenkglenks M*. A collaboration of the MARTA (MAking Randomized Trials Affordable) and ASPIRE (Adherence to Standard Protocol Items: REcommendations for interventional trials) Study Groups. Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation. PLoS One January 11, 2019; 14(1):e0210669. doi: 10.1371/journal.pone.0210669. [Epub]. https://doi.org/10.1371/journal.pone.0210669
* Shared last authorship.

2018

Schneider R, Schur N, Reinau D, Gut S, Schwenkglenks M, Meier C. Helsana Arzneimittelreport 2018.

Barbier M, Tomonaga Y, Schwenkglenks M. Robot-assisted surgery in women undergoing hysterectomy / Robotic-assisted radical prostatectomy compared to open radical prostatectomy for the treatment of localised prostate cancer. Swiss Medical Board, 2018

Romanens M, Szucs T, Sudano I, Adams A. Agreement of PROCAM and SCORE to assess cardiovascular risk in two different low risk European populations.Prev Med Rep. 2018 Dec 1;13:113-117

Hirschmann A, Lupatsch JE, Schwenkglenks M, Panje CM, Matter-Walstra K, Espeli V, Dedes KJ, Siano M; Swiss Group of Clinical Cancer Research (SAKK). Cost-effectiveness of nivolumab in the treatment of head and neck cancer. Oral Oncol. 2018 Dec;87:104-110

Schmidt H, Caldwell B, Mollet A, Leimer HG, Szucs T. An Industry Experience with Data Sharing. N Engl J Med. 2018 Nov 22;379(21):2081-2082

Wei W, Gruebner O, von Wyl V, Brüngger B, Dressel H, Ulyte A, Blozik E, Bähler C, Schwenkglenks M. Variation of preoperative chest radiography utilization in Switzerland and its influencing factors: a multilevel study with claims data. Sci Rep. 2018 Nov 30;8(1):17475

Kreis C, Doessegger E, Lupatsch JE, Spycher BD. Space-time clustering of childhood cancers: a systematic review and pooled analysis. Eur J Epidemiol. 2019 Jan;34(1):9-21

Griese-Mammen N, Hersberger KE, Messerli M, Leikola S, Horvat N, van Mil JWF, Kos M. PCNE definition of medication review: reaching agreement. Int J Clin Pharm. 2018 Oct;40(5):1199-1208

Mazzonna F, Salari P. Can a smoking ban save your heart?Health Econ. 2018 Oct;27(10):1435-1449

Tlhajoane M, Masoka T, Mpandaguta E, Rhead R, Church K, Wringe A, Kadzura N, Arinaminpathy N, Nyamukapa C, Schur N, Mugurungi O, Skovdal M, Eaton JW, Gregson S. A longitudinal review of national HIV policy and progress made in health facility implementation in Eastern Zimbabwe. Health Res Policy Syst. 2018 Sep 21;16(1):92

Mattli R, Wieser S, Probst-Hensch N, Schmidt-Trucksäss A, Schwenkglenks M. Physical inactivity caused economic burden depends on regional cultural differences. Scand J Med Sci Sports. 2019 Jan;29(1):95-104.

Lupatsch JE, Kreis C, Korten I, Latzin P, Frey U, Kuehni CE, Spycher BD. Neighbourhood child population density as a proxy measure for exposure to respiratory infections in the first year of life: A validation study.PLoS One. 2018 Sep 12;13(9):e0203743

Weber WP, Tausch C, Hayoz S, Fehr MK, Ribi K, Hawle H, Lupatsch JE, Matter-Walstra K, Chiesa F, Dedes KJ, Berclaz G, Lelièvre L, Hess T, Güth U, Pioch V, Sarlos D, Leo C, Canonica C, Gabriel N, Zeindler J, Cassoly E, Andrieu C, Soysal SD, Ruhstaller T, Fehr PM, Knauer M; Swiss Group for Clinical Cancer Research (SAKK). Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial. Ann Surg Oncol. 2018 Sep;25(9):2632-2640

Schur N, Brugaletta S, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Valgimigli M, Serruys PW, Ademi Z, Schwenkglenks M, Sabaté M. Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial. PLoS One. 2018 Aug 16;13(8):e0201985

Panje CM, Dedes KJ, Matter-Walstra K, Schwenkglenks M, Gautschi O, Siano M, Aebersold DM, Plasswilm L, Lupatsch JE; Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). Radiother Oncol. 2018 Nov;129(2):257-263

Muehlematter UJ, Nagel HW, Becker A, Mueller J, Vokinger KN, de Galiza Barbosa F, Ter Voert EEGT, Veit-Haibach P, Burger IA. Impact of time-of-flight PET on quantification accuracy and lesion detection in simultaneous 18F-choline PET/MRI for prostate cancer. EJNMMI Res. 2018 May 31;8(1):41

Sheikh S, Biundo E, Courcier S, Damm O, Launay O, Maes E, Marcos C, Matthews S, Meijer C, Poscia A, Postma M, Saka O, Szucs T, Begg N. A report on the status of vaccination in Europe. Vaccine. 2018 Aug 9;36(33):4979-4992

Leon-Reyes S, Schäfer J, Früh M, Schwenkglenks M, Reich O, Schmidlin K, Staehelin C, Battegay M, Cavassini M, Hasse B, Bernasconi E, Calmy A, Hoffmann M, Schoeni-Affolter F, Zhao H, Bucher HC. Cost Estimates for Human Immunodeficiency Virus (HIV) Care and Patient Characteristics for Health Resource Use From Linkage of Claims Data With the Swiss HIV Cohort Study. Clin Infect Dis. 2019 Feb 15;68(5):827-833

Ademi Z, Tomonaga Y, van Stiphout J, Glinz D, Gloy V, Raatz H, Bucher HC, Schwenkglenks M. Adaptation of cost-effectiveness analyses to a single country: the case of bariatric surgery for obesity and overweight. Swiss Med Wkly. 2018 Jun 12;148:w14626

Merritt MW, Sutherland CS, Tediosi F.EthicalConsiderations for Global Health Decision-Making: Justice-Enhanced Cost-Effectiveness Analysis of New Technologies for Trypanosoma brucei gambiense. Public Health Ethics. 2018 Jul 18;11(3):275-292

Tomonaga Y, Ten Haaf K, Frauenfelder T, Kohler M, Kouyos RD, Shilaih M, Lorez M, de Koning HJ, Schwenkglenks M, Puhan MA. Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study. Lung Cancer. 2018 Jul;121:61-69

Szucs TD, Szillat KP, Blozik E. Budget impact model for oncopharmacogenetics from the perspective of mandatory basic health insurance in Switzerland using the example of breast cancer. Pharmgenomics Pers Med. 2018 Apr 23;11:67-69

Keller F, Dhaini S, Briel M, Henrichs S, Höchsmann C, Kalbermatten D, Künzli N, Mollet A, Puelacher C, Schmidt-Trucksäss A, von Niederhäusern B, De Geest S. How to Conceptualize and Implement a PhD Program in Health Sciences-The Basel Approach. J Med Educ Curric Dev. 2018 Apr 24;5:2382120518771364

Moehrlen T, Szucs T, Landolt MA, Meuli M, Schiestl C, Moehrlen U. Trauma mechanisms and injury patterns in pediatric burn patients. Burns. 2018 Mar;44(2):326-334

Wieser S, Riguzzi M, Pletscher M, Huber CA, Telser H, Schwenkglenks M. How much does the treatment of each major disease cost? A decomposition of Swiss National Health Accounts. Eur J Health Econ. 2018 Nov;19(8):1149-1161

Reinau D, Schwenkglenks M, Früh M, Signorell A, Blozik E, Meier CR. Glucocorticoids and the Risk of Peptic Ulcer Bleeding: Case-Control Analysis Based on Swiss Claims Data. Drug Saf. 2018 Jul;41(7):725-730

Speich B, von Niederhäusern B, Blum CA, Keiser J, Schur N, Fürst T, Kasenda B, Christ-Crain M, Hemkens LG, Pauli-Magnus C, Schwenkglenks M, Briel M; MAking Randomized Trials Affordable (MARTA) Group. Retrospective assessment of resource use and costs in two investigator-initiated randomized trials exemplified a comprehensive cost item list. J Clin Epidemiol. 2018 Apr;96:73-83

Speich B, von Niederhäusern B, Schur N, Hemkens LG, Fürst T, Bhatnagar N, Alturki R, Agarwal A, Kasenda B, Pauli-Magnus C, Schwenkglenks M, Briel M1; MAking Randomized Trials Affordable (MARTA) Group. Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data. J Clin Epidemiol. 2018 Apr;96:1-11

Fürst T, Salari P, Llamas LM, Steinmann P, Fitzpatrick C, Tediosi F. Global health policy and neglected tropical diseases: Then, now, and in the years to come. PLoS Negl Trop Dis. 2017 Sep 14;11(9):e0005759.

Vokinger KN, Kesselheim AS, Avorn J, Sarpatwari A. Strategies That Delay Market Entry of Generic Drugs. JAMA Intern Med. 2017 Nov 1;177(11):1665-1669

2017

Schneider R, Schur N, Reinau D, Schwenkglenks M, Meier C. Helsana Arzneimittelreport 2017.

Kastien-Hilka T, Rosenkranz B, Schwenkglenks M, et al. Association between Health-Related Quality of Life and Medication Adherence in Pulmonary Tuberculosis in South Africa. Front Pharmacol. 2017 Dec 18; 8:919

Speich B, von Niederhäusern B, Blum CA, et al (including Schwenkglenks M). Randomized Trials Affordable (MARTA) Group. Retrospective assessment of resource use and costs in two investigator-initiated randomised trials exemplified a comprehensive cost item list. J Clin Epidemiol. 2017 Dec 29

Speich B, von Niederhäusern B, Schur N, et al (including Schwenkglenks M). Randomized Trials Affordable (MARTA) Group. Systematic review on costs and resource use of randomised clinical trials shows a lack of transparent and comprehensive data. J Clin Epidemiol. 2017 Dec 26.

Ademi Z, Pfeil AM, Hancock E, et al (including Schwenkglenks M). Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction. Swiss Med Wkly. 2017 Nov

Ademi Z, Sutherland CS, Van Stiphout J, Michaud J, Tanackovic G, Schwenkglenks. M. A systematic review of cost-effectiveness analysis of screening interventions for assessing the risk of venous thromboembolism in women considering combinedoral contraceptives. J Thromb Thrombolysis. 2017 Nov;44(4):494-506.

Conen D, Rodondi N, Mueller A, et al (including Schwenkglenks M). Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillation. Swiss Med Wkly. 2017 Jul

Blank PR, Ademi Z, Lu X, Szucs TD, Schwenkglenks M. Herpes zoster vaccine: A health economic evaluation for Switzerland. Hum Vaccin Immunother. 2017 Jul 3;13(7):1495-1504.

Kastien-Hilka T, Rosenkranz B, Sinanovic, et al (including Schwenkglenks M). Health-related quality of life in South African patients with pulmonary tuberculosis. PLoS One. 2017 Apr 20; 12(4)

Schandelmaier S, Tomonaga Y, Bassler D, et al (including Schwenkglenks M). remature Discontinuation of Pediatric Randomized Controlled Trials: A Retrospective Cohort Study. J Pediatr. 2017 May; 184:209-214.e1.

Matter-Walstra K, Schwenkglenks M, Dedes KJ. Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting. Breast Cancer Res Treat. 2017 Jun;163(3):635

Biétry FA, Pfeil AM, Reich O, Schwenkglenks M, et al. Benzodiazepine Use and Risk of Developing Alzheimer's Disease: A Case-Control Study Based on Swiss Claims Data. CNS Drugs. 2017 Mar;31(3):245-251.

Aichmair A, Burgstaller JM, Schwenkglenks M et al.; LSOS Study Group. Cost-effectiveness of conservative versus surgical treatment strategies of lumbar spinal stenosis in the Swiss setting: analysis of the prospective multicenter Lumbar Stenosis Outcome Study (LSOS). Eur Spine J. 2017 Feb;26(2):501-509.

Schmutz C, Mäusezahl D, Bless PJ, et al (including Schwenkglenks M). Estimating healthcare costs of acute gastroenteritis and human campylobacteriosis in Switzerland. Epidemiol Infect. 2017 Mar;145(4):627-641.

Matter-Walstra KW, Achermann R, Rapold R, et al (including Schwenkglenks M and Szucs TD) Days spent in acute care hospitals at the end of life of cancer patients in four Swiss cantons: a retrospective database study (SAKK 89/09). Eur J Cancer Care (Engl). 2017 Jul;26(4).

Gautschi O, Rothschild SI, Li Q, Matter-Walstra, et al. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clin Lung Cancer. 2017 May;18(3):303-309.

Ademi Z, Pasupathi K, Liew D. Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective. Appl Health Econ Health Policy. 2017 Jun;15(3):363-374.

Blank PR, Szucs TD. Sozialer und ökonomischer Nutzen der Impfung gegen Influenza. Praxis (Bern 1994). 2017;106(11):589-593.

Jain AB, Mollet A, Szucs TD. Regulatory watch: Structural and procedural characteristics of international regulatory authorities. Nat Rev Drug Discov. 2017 Sep;16(9):594.

Szucs TD, Weiss M, Klaus G. The enigma of value: in search of affordable and accessible health care. Eur J Health Econ. 2017 Jul;18(6):667-670.

Sutherland CS, Stone CM, Steinmann P, et al. Seeing beyond 2020: an economic evaluation of contemporary and emerging strategies for elimination of Trypanosoma brucei gambiense. Lancet Glob Health. 2017 Jan;5(1): e69-e79.

2016

Biétry F, Schur N, Reinau D, Becker C, Schwenkglenks M, Meier C. Helsana Arzneimittelreport 2016.

Matter-Walstra K, Schwenkglenks M, Aebi S, et al. A Cost-Effectiveness Analysis of Nivolumab  versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing. J Thorac Oncol. 2016;11(11):1846-1855.

Matter-Walstra K, Ruhstaller T, Klingbiel D, et al. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing:  a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK). Breast Cancer  Res Treat. 2016;158(1):51-7.

Matter-Walstra K, Braun R, Kolb C, et al. Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors. Br J Dermatol. 2016;174(2):463.

Matter-Walstra K, Schwenkglenks M, Betticher D, et al. Bevacizumab Continuation Versus

Treatment Holidays After First-Line Chemotherapy With Bevacizumab in Patients With Metastatic Colorectal Cancer: A Health Economic Analysis of a Randomized Phase 3 Trial (SAKK 41/06).  Clin Colorectal Cancer. 2016;15(4):314-320.e2.

Matter-Walstra K, Ademi Z. Understanding literature-based health economic analyses in oncology. Schweizerisches Krebsbulletin. 2016;4:327.

Gautschi O, Li Q, Matter-Walstra K, Betticher D, et al. 143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC:  Results of the expanded SAKK19/09 trial. J Thorac Oncol. 2016;11(4 Suppl):S120.

Rochlitz C, Bigler M, von Moos R, et al (including Matter-Walstra K). SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer  – a multicenter, randomized phase III trial. BMC Cancer. 2016;16(1):780.

Schwenkglenks M, Matter-Walstra K. Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments. Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):207-19.

Schandelmaier S, Conen K, von Elm E, et al (including Schwenkglenks M). Planning and reporting of quality-of-life outcomes in cancer trials. Ann Oncol. 2016;27(1):209.

Biétry FA, Reich O, Schwenkglenks M, et al. Statin use and risk of cholecystectomy – A case-control analysis using Swiss claims data. Expert Opin Drug Saf. 2016;15(12):1577-1582.

Kastien-Hilka T, Abulfathi A, Rosenkranz B, et al (including Schwenkglenks M). Health-related  quality of life and its association with medication adherence in active pulmonary tuberculosis-  a systematic review of global literature with focus on South Africa. Health Qual Life Outcomes. 2016;14:42.

Kasenda B, von Elm E, You JJ, et al (including Schwenkglenks M). Agreements between Industry and Academia on Publication Rights: A Retrospective Study of Protocols and Publications of Randomized Clinical Trials. PLoS Med. 2016;13(6):e1002046.

Schandelmaier S, von Elm E, You JJ, et al (including Schwenkglenks M). Premature Discontinuation of Randomized Trials in Critical and Emergency Care: A Retrospective Cohort Study. Crit Care Med. 2016;44(1):130-7.

Kastien-Hilka T, Rosenkranz B, Bennett B, et al (including Schwenkglenks M). How to Evaluate Health-Related Quality of Life and Its Association with Medication Adherence in Pulmonary Tuberculosis – Designing a Prospective Observational Study in South Africa. Front Pharmacol. 2016;7:125.

Ademi Z, Gloy V, Glinz D, et al. Cost-effectiveness of primarily surgical versus primarily conservative treatment of acute and subacute radiculopathies due to intervertebral disc herniation from the Swiss perspective. Swiss Med Wkly. 2016;146:w14382.

Ademi Z, Pasupathi K, Liew D. Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective. Medicine (Baltimore). 2016;95(18):e3531.

Burton NW, Ademi Z, Best S, et al. Efficacy of brief behavioral counselling by allied health professionals to promote physical activity in people with peripheral arterial disease (BIPP): study protocol for a multi-center randomized controlled trial. BMC Public Health. 2016;16(1):1148.

Collaborators (769) including Ademi Z, Global, regional, and national life expectancy, all-cause  mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459-1544.

Collaborators (630) including Ademi Z, Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545-1602

Collaborators (644) including Ademi Z, Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks,  1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1659-1724.

Szucs TD, Stoffel AW. Nutrition and health – Why payors should get involved. Nutrition. 2016;32(5):615-6.

Risch M, Risch L, Purde MT, Renz H, et al (including Szucs TD). Association of the cystatin  C/creatinine ratio with the renally cleared hormones parathyroid hormone (PTH) and brain natriuretic peptide (BNP) in primary care patients: a cross-sectional study. Scandinavian Journal of Clinical and Laboratory Investigation. 2016.

Grous P, Anchisi S, Szucs TD. Cancer patient’s contribution to reduce chemotherapy related burden of travel: what would chemotherapy patients agree to do? Open Public Health Journal 2016.

Szucs TD, Blozik E, Reich O. Die moderne Psychiatrie im Spannungsfeld zwischen Machbarkeit und Finanzierbarkeit. Swiss Archives of Neurology and Psychiatry. 2016;167(06):177-183.

Bräm C, Szucs TD. Is It Desirable that I Must Disclose My Genetic Data to Swiss Private Medical Insurances? Public Health Genomics. 2016;19(5):251-9.

Szucs TD, Weiss M, Klaus G. The enigma of value: in search of affordable and accessible  health care. Eur J Health Econ. 2016 Dec 2.

2015

Biétry F, Schur N, Pfeil A, Schwenkglenks M, Meier C. Helsana Arzneimittelreport 2015.

Jürgens V, Ess S, Schwenkglenks M, et al. Using lung cancer mortality to indirectly approximate smoking patterns in space. Spat Spatiotemporal Epidemiol. 2015 Jul-Oct; 14-15:23-31. Epub 2015 Jul 1.

Schandelmaier S, Conen K, von Elm E, et al. Schwenkglenks M. Planning and reporting of quality-of-life outcomes in cancer trials. Ann Oncol. 2015 Sep; 26(9):1966-73. Epub 2015 Jun 30. Erratum in: Ann Oncol. 2016 Jan; 27(1):209.

Blank PR, Filipits M, Dubsky P, et al. Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients. Pharmacoeconomics. 2015 Feb;33(2):179-90.

Belleli R, Fisch R, Szucs TD. Regulatory watch: Efficiency indicators for new drugs approved by the FDA from 2003 to 2013. Nat Rev Drug Discov. 2015 Mar;14(3):156.

Pfeil AM, Reich O, Guerra IM, Cure S, et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. PLoS One. 2015 May 14;10(5).

Pfeil AM, Allcott K, Pettengell R, et al. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer. 2015 Feb; 23(2):525-45. Epub 2014 Oct 7.

Pfeil AM, Imfeld P, Pettengell R, et al. Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD). Ann Hematol. 2015 Mar; 94(3):421-9. Epub 2014 Sep 16.

Gutzwiller FS, Pfeil AM, Ademi Z, et al. Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland. Pharmacoeconomics. 2015 Dec; 33(12):1311-24.

Vulsteke C, Pfeil AM, Maggen C, Schwenkglenks M et al. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients. Breast Cancer Res Treat. 2015 Jul; 152(1):67-76. Epub 2015 May 28.

Vulsteke C, Pfeil AM, Schwenkglenks M, et al. Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel. Breast Cancer Res Treat. 2014 Oct; 147(3):557-70. Epub 2014 Aug.

Matter-Walstra K, Braun R, Kolb C, et al. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting. Br J Dermatol. 2015 Dec; 173(6):1462-70. Epub 2015 Nov 7.

Matter-Walstra KW, Achermann R, Rapold R, et al. Cancer-related therapies at the end of life in hospitalized cancer patients from four Swiss cantons: SAKK 89/09. Oncology. 2015; 88(1):18-27. Epub 2014 Sep 26.

Kovacević A, Dragojević-Simić V, Rancić N, et al. Matter-Walstra K.  End-of-life costs of medical care for advanced stage cancer patients.Vojnosanit Pregl. 2015 Apr; 72(4):334-41.

Matter-Walstra KW, Greiner M, Cusini A, et al. Stringent adherence to a cytomegalovirus-prevention protocol is associated with reduced overall costs in the first 6 months after kidney transplantation. Transpl Infect Dis. 2015 Jun;17(3):342-9. Epub 2015 May 19.

Chowdhury E, Ademi Z, Moss J, et al. 4B.04: COST-UTILITY OF ANGIOTENSIN-CONVERTING ENZYME INHIBITOR COMPARED TO THIAZIDE DIURETIC -BASED TREATMENT FOR HYPERTENSION IN ELDERLY AUSTRALIANS CONSIDERING DIABETES AS COMORBIDITY. J Hypertens. 2015 Jun; 33 Suppl 1:e53-7.

Chowdhury EK, Langham RG, Ademi Z, et al; Second Australian National Blood Pressure Study Management Committee. Rate of change in renal function and mortality in elderly treated hypertensive patients. Clin J Am Soc Nephrol. 2015 Jul 7; 10(7):1154-61. Epub 2015 Apr 21.

Chowdhury EK, Ademi Z, Moss JR et al; Second Australian National Blood Pressure Study Management Committee. Cost-utility of angiotensin-converting enzyme inhibitor-based treatment compared with thiazide diuretic-based treatment for hypertension in elderly Australians considering diabetes as comorbidity. Medicine (Baltimore). 2015 Mar; 94(9):e590.

Feigin VL, Mensah GA, Norrving B, et al; GBD 2013 Stroke Panel Experts Group including Ademi Z. Atlas of the Global Burden of Stroke (1990-2013): The GBD 2013 Study. Neuroepidemiology. 2015; 45(3):230-6. Epub 2015 Oct 28.

Barker-Collo S, Bennett DA, Krishnamurthi RV, et al; GBD 2013 Writing Group; GBD 2013 Stroke Panel Experts Group including Ademi Z. Sex Differences in Stroke Incidence, Prevalence, Mortality and Disability-Adjusted Life Years: Results from the Global Burden of Disease Study 2013. Neuroepidemiology. 2015; 45(3):203-14. Epub 2015 Oct 28.

Krishnamurthi RV, Moran AE, Feigin VL, et al; GBD 2013 Stroke Panel Experts Group including Ademi Z. Stroke Prevalence, Mortality and Disability-Adjusted Life Years in Adults Aged 20-64 Years in 1990-2013: Data from the Global Burden of Disease 2013 Study. Neuroepidemiology. 2015; 45(3):190-202. Epub 2015 Oct 28.

Krishnamurthi RV, deVeber G, Feigin VL, et al; GBD 2013 Stroke Panel Experts Group Including Ademi Z. Stroke Prevalence, Mortality and Disability-Adjusted Life Years in Children and Youth Aged 0-19 Years: Data from the Global and Regional Burden of Stroke 2013. Neuroepidemiology. 2015;45(3):177-89. Epub 2015 Oct 28.

Feigin VL, Krishnamurthi RV, Parmar P, et al; GBD 2013 Writing Group; GBD 2013 Stroke Panel Experts Group including Ademi Z.Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study. Neuroepidemiology. 2015; 45(3):161-76. Epub 2015 Oct 28.

GBD 2013 DALYs and HALE Collaborators including Ademi Z. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015 Nov 28; 386(10009):2145-91. Epub 2015 Aug 28.

GBD 2013 Mortality and Causes of Death Collaborators includingAdemi Z. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jan 10;385(9963):117-71. Epub 2014 Dec 18.